A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR).

Trial Profile

A PHASE II STUDY TO ASSESS EFFICACY AND SAFETY OF PIOGLITAZONE (ACTOS) AS ADD-ON THERAPY TO IMATINIB MESYLATE (GLEEVEC) IN CHRONIC PHASE CHRONIC MYELOGENOUS LEUKAEMIA (CP-CML) PATIENTS IN MAJOR MOLECULAR RESPONSE (MMR).

Completed
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2017

At a glance

  • Drugs Pioglitazone (Primary) ; Imatinib
  • Indications Chronic myeloid leukaemia
  • Focus Proof of concept; Therapeutic Use
  • Acronyms ACTIM
  • Most Recent Events

    • 27 Dec 2016 Status changed from recruiting to completed, as per the results published in the Cancer journal.
    • 27 Dec 2016 Results published in the Cancer
    • 08 Jun 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top